Phio Pharmaceuticals Corp. - PHIO STOCK NEWS

Phio Pharmaceuticals Corp. (Nasdaq: PHIO) announced preclinical data at the 9th Immunotherapy of Cancer Conference showing that its lead product, PH-762, enhances T cell populations with stem cell-like characteristics. This improvement is expected to increase T cell persistence in vivo, thereby enhancing anti-tumor activity. The study indicates that PH-762 could downregulate PD-1, a target in immunotherapy, allowing T cells to kill cancer cells more effectively. A first-in-human clinical trial of PH-762 for advanced melanoma is currently underway.

Phio Pharmaceuticals Corp. (Nasdaq: PHIO) announced the acceptance of six abstracts for poster presentations at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) from November 10-12, 2022, in Boston, MA. The abstracts will cover in vitro and in vivo tumor efficacy and clinical work on INTASYL compounds targeting various immune checkpoints. The company aims to advance its immuno-oncology efforts using its self-delivering RNAi therapeutic platform, particularly focusing on the PD-1 gene silencing compound PH-762.

Phio Pharmaceuticals Corp. (Nasdaq: PHIO) announced the initiation of a first-in-human clinical trial for PH-762 targeting advanced melanoma, with top-line data expected in Q1 2023. The company plans to begin a clinical trial for PH-762 combined with double positive tumor infiltrating lymphocytes by Q4 2022 in collaboration with AgonOx. Financial results revealed a 16% decrease in R&D expenses to $1.3 million, contributing to a 6% reduction in net loss to $2.5 million. Despite cash reserves dropping to $18 million, the company expects to fund operations through Q4 2023.

Phio Pharmaceuticals Corp. (Nasdaq: PHIO) presented a trial-in-progress poster detailing its Phase 1b clinical trial of PH-762, a self-delivering RNAi targeting PD-1, for advanced melanoma at the 2022 ASCO annual meeting. The study evaluates the safety, pharmacokinetics, and potential tumor responses of neoadjuvant use of PH-762 via intratumoral injection. With ongoing trials at Gustave Roussy Institute, the company aims to fill the gap in neoadjuvant treatments for this patient group. Initial results suggest a robust inhibition of tumor growth and minimal systemic side effects, marking progress in immunotherapy options.

Phio Pharmaceuticals Corp. (Nasdaq: PHIO) announced new preclinical data on May 16, 2022, demonstrating that its self-delivering RNAi compound, PH-894, can enhance CAR-T cell products by silencing BRD4 during the activation and expansion phases. This improvement could address challenges such as cell exhaustion, increasing the effectiveness of CAR-T therapies for solid tumors. The data will be presented at the ASGCT Annual Meeting in Washington D.C. from May 16-19, 2022.

Phio Pharmaceuticals Corp. (Nasdaq: PHIO) has opened enrollment for its first-in-human clinical trial of PH-762, aimed at treating advanced melanoma. The study will assess safety and anti-tumor activity, with initial data expected in Q1 2023. Phio is also finalizing IND-enabling studies for PH-894, targeting patients unresponsive to PD-1 therapy. For Q1 2022, the company reported a net loss of $2.6 million, down from $3.4 million in Q1 2021, due to reduced R&D expenses. Cash reserves stand at $20.5 million, sufficient to fund operations into Q2 2023.

Phio Pharmaceuticals Corp. (Nasdaq: PHIO) announced the departure of Dr. Gerrit Dispersyn as President and CEO effective May 5, 2022. Dispersyn, who joined in 2017, played a key role in transitioning the company towards immuno-oncology therapeutics, particularly through the INTASYL™ platform targeting cutaneous melanoma. Following his departure, Dr. Geert Cauwenbergh, the former CEO, will serve as Principal Executive Officer until a new CEO is appointed. This leadership change comes as the company progresses in developing its RNAi therapeutic platform.

Phio Pharmaceuticals Corp. (Nasdaq: PHIO) announced its participation in the 2022 American Society of Clinical Oncology (ASCO) annual meeting, set for June 3-7, 2022, in Chicago, IL. The company will present a trial-in-progress poster titled "A First-in-Human, Phase 1b Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Anti-Tumor Activity of Neoadjuvant Use of PH-762 Administered Intratumorally in Subjects with Advanced Melanoma". The poster's author is Professor Caroline Robert, and the presentation is scheduled for June 6, 2022, from 1:15 to 4:15 p.m. Central Time.

Phio Pharmaceuticals Corp. (Nasdaq: PHIO) announced the presentation of new preclinical data on PH-894, an innovative therapeutic based on their proprietary self-delivering RNAi platform, at the ASGCT 25th Annual Meeting from May 16-19, 2022. This research focuses on improving the phenotype of HER2-CAR-T cells during expansion. The poster session is scheduled for May 16, 2022, from 5:30 PM - 6:30 PM EDT at the Walter E. Washington Convention Center in Washington, D.C., highlighting the company's advancements in immuno-oncology therapeutics.